Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498312 | 0.88 | KDM4E (0.47) | TRPV1SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL6496665 | 0.88 | HSD17B10 (0.46) | TRPV1SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL6504061 | 0.81 | KDM4E (0.52) | SMN1; SMN2LMNAHSD17B10KDM4EANPEP | |
| SCHEMBL27493374 | 0.80 | MAOA (0.57) | SMN1; SMN2ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL6497834 | 0.74 | KMT2A (0.52) | TRPV1SMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL2007222 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL3985690 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL619526 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL2407620 | 0.72 | HTT (0.47) | TRPV1SMN1; SMN2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL4022009 | 0.72 | TRPV1 (0.70) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| CN-1070480-C | 2-amino-benzoxanones for the treatment of viral infections | SEARLE & CO (US) | 2001-09-05 | — | — | CN | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | TRPV1 1835/4885SMN1; SMN2 1354/4885ALDH1A1 1022/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | TRPV1 2053/4885SMN1; SMN2 1274/4885ALDH1A1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.